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I have co-edited this report at the invitation of Mariko Watanabe, a visiting 
scholar at Peking University and Institute of Developing Economies. The report 
is comprised of two parts about pharmaceutical industry in China. Part I covers 
the basic condition and institution of the pharmaceutical market, in particular the 
demand and institutions related to price setting and patents. Part II discuses the 
strategies of pharmaceutical firms: their price setting policy and their innovation 
strategy and subsequent management. The pharmaceutical industry is an 
important sector for both the country’s economic development and its national 
health - a sector where competition is very acute and intervention by the 
government is deep, and a lot of problems remain to be solved.  
I have known Ms. Watanabe for many years, and she is very capable and 
works very diligently. Professor Shi Luwen and Instructor Chen Jing, from the 
Health Science Center of Peking University, and Ms. Cao Jinyan, Vice head of 
the Intellectual Property Development Center at the State Intellectual Property 
Office, also supported this research project. In order to meet their request, I 
agreed to co-edit this report and also contributed one chapter co-authored with Dr. 
Xiang Anbo.  
This report consists of 5 chapters: Chapter 1, “Demand and Institutions,” 
introduces the size and structural features of pharmaceutical demand, such as the 
medical insurance system and its drug catalogues, in China and how it differs 
from those abroad. The author also introduces how a structural problem such as 
“Feeding Hospitals with Drugs” affects the demand for drugs in China. Chapter 2, 
“Price Setting Institutions,” presents the drug pricing policy by introducing the 
drug price management policy of the Chinese government, and discusses the 
auctions and central tendering system’s impacts on the price of drugs. Chapter 3, 
“Patents, New Drug Protection and the Pharmaceutical Industry in China,” states 
the historical development of the patent protection system in China and its impact 
on the pharmaceutical industry. The authors state that patent protection in China 
is improving gradually and acts as a very important factor in the development of 
the industry, while at the same time we need to be careful to balance the level of 
patent protection with China’s current stage of development. Chapter 4, “Pricing 
Strategy of Firms,” discusses how firms set their prices under the current 
institutions: first, it formally analyzes the impact of the “Feeding Hospitals with 
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Drugs” type demand on the price setting strategy, and cross-checks predictions 
against the actual data for a class of anti- high-cholesterol drug Statins in China, 
before presenting recommendations for what kind of institutions could induce 
better pricing by firms and hospitals. Chapter 5, “Innovation: Motivation and 
Incentive” introduces how the Chinese pharmaceutical industry conducts research, 
development, and innovation; it points out that although innovation systems in 
Chinese pharmaceuticals are not at such an “innovative” stage as a whole, we 
cannot neglect the fact that a few well-managed firms have already made much of 
innovation and have built up their own innovation systems. Government policies 
on promoting innovation are also starting to have an effect. 
We warmly welcome the reader’s criticism of whether these 5 chapters 
describe the current situation of the industry well, and whether its view points 
and claims are appropriate. At this point, I would like to note two points. 
First, we must recognize that special conditions in China’s development and 
reform have substantially affected the Chinese pharmaceutical industry. Since the 
1970s, China has been challenged by two different problems: the development of, 
and transition from, the market. Due to a lack of experience and shortages in 
fiscal capacity until the 1990s (fiscal capacity was very weak due to the Cultural 
Revolution in the earlier period, and the fiscal contracting mechanism in later 
times),  “activating by decentralization” has been a key remedy for reforms in 
various fields for a long time. “Activating by decentralization” implies the 
introduction of market competition when the weak fiscal capability of the central 
government cannot afford the necessary cost of reform, and so the appropriate 
medical insurance and drug management policies for the market economy had not 
yet been built. All these problems led to the phenomenon referred to as “Feeding 
Hospitals with Drugs.” This report notes that the phenomenon induced huge 
problems in both the drug market and demand. Fortunately, once society had 
fully perceived the problem, fiscal capacity also improved. Currently, society has 
come to a consensus to resolve this problem by increasing input from the 
government while simultaneously utilizing the market mechanisms. 
Secondly, we must recognize that the institutional environment affects the 
innovation strategy of Chinese pharmaceutical firms. Some argue that the 
innovation capacity of Chinese pharmaceuticals is far behind their counterparts in 
India. There are several opinions and controversies surrounding how to view this 
problem. However, we clearly perceive that the difference in China’s institutional 
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setting has affected the innovation ability of the Chinese pharmaceutical industry. 
For example, China recognized product patents in 1993, when Chinese firms had 
sufficient research and development capacity. On the contrary, India did not 
endorse product patents for drugs until 2005. This difference in patent protection 
was advantageous for Indian counterparts. Furthermore, due to the 
underdeveloped capital market and local protectionism among other, Chinese 
pharmaceuticals found it difficult to finance research and development, not to 
mention merging research or innovation companies. The traditional system and 
its path dependency substantially affected Chinese firms capacity for innovation. 
Currently, a change is taking place in Chinese pharmaceuticals’ capacity for 
innovation: there are a group of firms with a basic capacity for research and 
development; and the rich numbers of scientist in research institutions, 
cooperating with firms and academics, are advantageous and complement the 
Chinese pharmaceuticals less developed capacity for innovation. Thus 
Governments are eagerly promoting basic research and new drug development. 
By bearing the above two points in mind, we can more deeply understand 
the market, the institutions, and the other problems that the Chinese 
pharmaceutical industry is faced with, along with their basic conditions. This 
represents the preface for this report. 
 
CHEN Xiaohong 
July 2007, Beijing 
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